FDA Inspection 1267912 — Wuhan Biocause Pharmaceutical Development Co., Ltd.
The FDA completed an inspection of Wuhan Biocause Pharmaceutical Development Co., Ltd. on March 14, 2025 in Wuhan. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- March 14, 2025
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Wuhan (China)